Alle Fälle anzeigen
ORD 22246/2025
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieVerfahrensführungsanordnungen
- Parteien
- Kläger
- Sanofi SA
- Sanofi Winthrop Industrie
- Sanofi-Aventis Deutschland GmbH
- Sanofi Belgium
- Sanofi-Aventis GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (McDermott Will & Schulte)Beklagte- Accord Healthcare S.L.U.
- Accord Healthcare GmbH (AT)
- Accord Healthcare B.V.
- Accord Healthcare GmbH (DE)
- Accord Healthcare Italia Srl
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare AB
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Zentiva France
- Zentiva Pharma GmbH
- Zentiva, k.s.
Vertreter: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing) - Division
- Munich LD
- Richter
- Matthias Zigann · Presiding judge and judge-rapporteur
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 17. Juli 2025
Entscheidungen
- 2025-07-17Generic Order
The Local Division Munich issued a case management order following an interim conference in parallel infringement proceedings by Sanofi against multiple generics manufacturers (Accord, STADA, Reddy, Zentiva) concerning EP 2 493 466, noting EPO BoA uphold of the patent, scheduling the oral hearing for October 2025, and addressing expert evidence and confidentiality of interim damages calculations.
Rechtsfragen:Case management post-interim conference (R.105.5 RoP)EPO BoA validity decisionExpert evidence – hot tubbingConfidentiality of interim damages calculationsParallel French national invalidity proceedings
Dokumente
- 4C95D6CFCB3E8067E3A0756CB64E39E7_en.pdf2025-07-17EN